For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | - |
| Research and development, net of tax credits | 3,940 | 3,669 | 4,978 | 3,963 |
| General and administrative | 3,263 | 3,759 | 5,167 | 3,742 |
| Commercial | 4,626 | 5,103 | 10,378 | 1,911 |
| Loss from operations | -11,829 | -12,531 | -20,523 | -9,616 |
| Interest income | 874 | 516 | 697 | 1,080 |
| Interest expense | 967 | 951 | 935 | 903 |
| Net loss and comprehensive loss | -11,922 | -12,966 | -20,761 | -9,439 |
| Earnings per share, basic | -0.12 | -0.2 | -0.31 | -0.14 |
| Earnings per share, diluted | -0.12 | -0.2 | -0.31 | -0.14 |
Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. (MIST)